4D pharma plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Duncan Joseph Peyton
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9 Bond Court Leeds United Kingdom LS1 2JZ
- IPO Date
- Mar 22, 2021
- CIK
- 0001830162
- Website
- 4dpharmaplc.com
- Similar Companies
- Business
- 4D pharma plc (LBPS) is a clinical-stage biotechnology company focused on the research, development, and commercialization of live biotherapeutic products derived from the gut microbiome to treat gastrointestinal and other diseases. The company develops proprietary product candidates including Blautix for irritable bowel syndrome and inflammatory bowel disease; MRx1234 and MRx05101 as oncology therapeutics for solid tumors; and MRx12942 for primary sclerosing cholangitis; along with other preclinical assets targeting immunotherapy and immuno-oncology indications. These live biotherapeutics consist of consortia of microbes selected and formulated based on 4D pharma's proprietary MicroRx® platform, which employs phenotypic screening and AI-driven analysis to identify optimal bacterial strains for specific disease modulation. Founded in 2014 and headquartered in York, United Kingdom, the company operates primarily in Europe with clinical trials and research activities extending to the United States and other regions, targeting patients in gastroenterology, oncology, and infectious diseases. In recent developments within the last two years, 4D pharma has advanced multiple product candidates into clinical stages, including ongoing Phase II trials for Blautix and Phase I/II studies for its oncology pipeline; formed strategic research collaborations with academic institutions and big pharma partners to expand its MicroRx® platform applications; and navigated financing rounds to support pipeline progression amid biotech sector challenges, with no major acquisitions or name changes reported.
4D pharma says phase II IBS results published in scientific journal
4D Pharma outlines phase II plans for promising cancer drug candidate
4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate
4D Pharma has a busy year ahead after a successful 12 months of clinical research
4D Pharma PLC soars after meeting endpoint early
4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
4D pharma sees early success as phase I/II cancer trial hits its efficacy target early
4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidates
4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma
4D pharma hails 'highly encouraging' data from its early-stage asthma trial
4D pharma hires new CFO
4D pharma says asthma live biotherapeutic shows ‘promising' early signs of clinical activity
4D pharma to present new insights from IBS study
4D Pharma interim results mark major milestones
4D Pharma interims marks major milestones
4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
4D pharma to display two posters showcasing positive data for cancer asset at oncology conference
4D pharma to display two posters showcasing positive data for cancer treatment at oncology conference